Abbott: Still A Dividend Growth Stalwart? – Seeking Alpha

Abbott: Still A Dividend Growth Stalwart? – Seeking Alpha: Last week Abbott Laboratories (ABT) announced that it plans to separate into two publicly traded companies around the end of 2012. One, retaining the Abbott name, will focus on diversified medical products. The other, “New Pharmaceutical Company,” will focus on research-based drugs. Both companies will be global leaders in their respective industries on the day they begin.

In the announcement, Abbott stated that the “two publicly traded companies will offer shareholders distinct opportunities given unique investment identities, business profiles and attributes,” and that the decision “builds on a decade of strategic and operational advancements.” Miles White, chairman and chief executive officer, stated


About EdR

Tant que les lions n’auront pas leurs propres historiens, les histoires de chasse continueront de glorifier le chasseur. (proverbe africain)

Posted on October 26, 2011, in Abbott, David Van Knapp, Dividend Growth. Bookmark the permalink. Leave a comment.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: